Biofrontera Inc. Common Stock (BFRI) Stock Price

BFRIStock

$1.51+51.45%52W

Market Cap$22.43M

P/E—

PEG Ratio—

Div yield—

Beta0.80

BFRI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)45.74%

Price vs S&P 500 (4W)28.48%

VGM Score75.67

Book Value / Share (Quarterly)$0.51

P/TBV (Annual)0.85x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.31%

Cash Flow / Share (Quarterly)$-0.78

Price vs S&P 500 (YTD)144.18%

Gross Margin (TTM)77.29%

Net Profit Margin (TTM)-25.66%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$-1.11

Revenue Growth (5Y)17.21%

EPS (Annual)$-1.04

ROI (Annual)-69.92%

Gross Margin (Annual)73.71%

Net Profit Margin (5Y Avg)-58.13%

Cash / Share (Quarterly)$0.53

Revenue Growth QoQ (YoY)17.42%

ROA (Last FY)-36.89%

Revenue Growth TTM (YoY)13.70%

EBITD / Share (TTM)$-1.01

ROE (5Y Avg)-251.27%

Operating Margin (TTM)-25.73%

Cash Flow / Share (Annual)$-1.15

P/B Ratio2.66x

P/B Ratio (Quarterly)1.55x

Net Income / Employee (Annual)$-125,400

EV / Revenue (TTM)0.34x

Net Interest Coverage (TTM)-22.36x

ROA (TTM)-49.87%

EPS Incl Extra (Annual)$-1.04

Current Ratio (Annual)1.52x

Quick Ratio (Quarterly)0.99x

3-Month Avg Trading Volume0.33M

52-Week Price Return51.45%

Revenue / Employee (TTM)$514,300

Tangible BV / Share (Quarterly)$0.29

P/S Ratio (Annual)0.39x

Asset Turnover (Annual)1.46x

52-Week High$1.55

Operating Margin (5Y Avg)-57.68%

EPS Excl Extra (Annual)$-1.04

CapEx CAGR (5Y)-35.56%

26-Week Price Return56.99%

Quick Ratio (Annual)1.21x

13-Week Price Return87.37%

Total Debt / Equity (Annual)0.44x

Current Ratio (Quarterly)1.20x

Enterprise Value$14.53M

Revenue / Share Growth (5Y)-38.64%

Asset Turnover (TTM)1.94x

Revenue / Employee (Annual)$496,500

Inventory Turnover (Annual)2.72x

Pretax Margin (Annual)-25.20%

Cash / Share (Annual)$0.55

3-Month Return Std Dev72.97%

Gross Margin (5Y Avg)53.37%

Net Income / Employee (TTM)$-132,000

EBITDA Interim CAGR (5Y)57.61%

ROE (Last FY)-100.53%

Net Interest Coverage (Annual)-22.53x

EPS Basic Excl Extra (Annual)$-1.04

Receivables Turnover (TTM)10.92x

Total Debt / Equity (Quarterly)0.78x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)6.62x

ROI (TTM)6.87%

P/S Ratio (TTM)0.37x

Pretax Margin (5Y Avg)-58.03%

Revenue / Share (Annual)$4.10

Tangible BV / Share (Annual)$0.67

Forward P/E504.41x

Price vs S&P 500 (52W)33.14%

Year-to-Date Return156.14%

5-Day Price Return1.39%

EPS Normalized (Annual)$-1.04

ROA (5Y Avg)-52.29%

Net Profit Margin (Annual)-25.26%

Month-to-Date Return24.79%

Cash Flow / Share (TTM)$-19.36

EBITD / Share (Annual)$-1.11

Operating Margin (Annual)-27.21%

LT Debt / Equity (Annual)0.44x

ROI (5Y Avg)-168.96%

LT Debt / Equity (Quarterly)0.78x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)2.72x

P/B Ratio (Annual)0.63x

Inventory Turnover (TTM)2.53x

Pretax Margin (TTM)-25.60%

Book Value / Share (Annual)$0.90

Price vs S&P 500 (13W)84.58%

Beta0.80x

Revenue / Share (TTM)$3.70

ROE (TTM)10.73%

52-Week Low$0.56

vGradeA

gGradeB

mGradeB

vgmGradeB

BFRI Earnings Surprise History

Q2 25-0.57est. -0.39

Q3 25-0.57est. -0.56

Q4 250.50est. 0.10

Q1 26-0.41est. -0.05

Q2 26-0.05est. -0.04

BFRI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
BFRIBiofrontera Inc. Common Stock	A	B	B	$1.51
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Biofrontera Inc. Common Stock

Biofrontera Inc is a US-based biopharmaceutical company specializing in photodynamic therapy treatments for dermatological conditions. The company commercializes Ameluz, an FDA-approved topical photosensitizer, along with proprietary RhodoLED lamps designed for the treatment of actinic keratoses, which are pre-cancerous skin lesions. This integrated product approach combines pharmaceuticals with medical devices to address a significant market opportunity in dermatology.